scholarly journals Comparison of Clinical Severity Improvement Degree between Acute Thrombotic Stroke Patients with Low and High Matrix Metalloproteinase-9 Levels

2020 ◽  
Keyword(s):  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Clinical Severity ◽  
Stroke Patients ◽  
High Matrix ◽  
Metalloproteinase 9

Abstract TMP22: Intravenous Glyburide Treatment is Associated with Reduced Matrix Metalloproteinase-9 in Human Acute Stroke

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Ly Pham ◽  
Sydney O’Connor ◽  
Karen Yarbrough ◽  
Sven Jacobson ◽  
Barney J Stern ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Active Form ◽  
Pilot Trial ◽  
Specific Inhibitor ◽  
Matrix Metalloproteinase 9 ◽  
Stroke Patients ◽  
Hemispheric Stroke ◽  
Intravenous Tissue Plasminogen Activator ◽  
Metalloproteinase 9

Background: Elevated matrix metalloproteinase-9 (MMP-9) following acute ischemic stroke is associated with blood-brain barrier breakdown and hemorrhagic conversion. Prior retrospective evidence suggests that sulfonylurea use may be associated with reduced risk of hemorrhagic conversion. We hypothesized that sulfonylureas may reduce MMP-9 level in stroke patients. Methods: Using serial plasma samples from six subjects in the Glyburide Advantage in Malignant Edema and Stroke Pilot trial (GAMES-Pilot), we evaluated the level of MMP-9 in human subjects presenting with large hemispheric stroke who were treated with intravenous glyburide (RP-1127). MMP-9 was measured in a control cohort with large ischemic stroke who were not treated with glyburide. Commercially available ELISA kits and gel zymography were used to measure MMP-9 at baseline and at approximately 48 hours after stroke. GAMES subjects had additional time points analyzed until approximately 84 hours after stroke. Results: Average MMP-9 level in glyburide-treated stroke patients was 47.2 ± 8.0 ng/mL compared to 143.4 ± 60.35 ng/mL in untreated control subjects (p=0.004). Zymography analysis demonstrated a significant decrease in the pro-enzyme but no change in the active form of MMP-9. There was no difference in the level of the MMP-9 specific inhibitor, TIMP-1. No subjects exhibited parenchymal hemorrhagic conversion on 24 hour head CT scan. Conclusions: Glyburide treatment in human stroke patients with large hemispheric stroke is associated reduced level of MMP-9. Elucidating the underlying mechanism of glyburide’s effect on MMP-9 and the risk of hemorrhagic conversion may highlight future directions of therapy, including in combination with intravenous tissue plasminogen activator (IV t-PA).

scholarly journals Association between Increased Matrix Metalloproteinase-9 (MMP-9) Levels with Hyperglycaemia Incidence in Acute Ischemic Stroke Patients

2018 ◽  
Vol 6 (11) ◽  
pp. 2067-2072 ◽  
Author(s):  
Ismail Setyopranoto ◽  
Rusdy Ghazali Malueka ◽  
Andre Stefanus Panggabean ◽  
I Putu Eka Widyadharma ◽  
Ahmad Hamim Sadewa ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Blood Levels ◽  
Stroke Patients ◽  
Reference Hospital ◽  
The Difference ◽  
Increased Activity ◽  
Metalloproteinase 9

BACKGROUND: Hyperglycemia is common in acute stroke patients. Hyperglycemia can induce the production of reactive oxygen species, causing increased activity of matrix metalloproteinase-9 (MMP-9). AIM: This study aimed to determine an association between the increased levels of MMP-9 and the incidence of hyperglycemia in acute ischemic stroke patients. METHODS: This is a case-control study. Acute ischemic stroke patients admitted to the Stroke Unit of a reference hospital in Yogyakarta, Indonesia was divided into the hyperglycemic and non-hyperglycemic group. Demographic and clinical characteristics of each subject were recorded, and blood levels of MMP-9 were measured. Seventy-one patients were recruited, 40 subjects in the hyperglycemic group and 31 subjects in the non-hyperglycemic group. RESULTS: The median levels of blood MMP-9 level in the hyperglycemic and non-hyperglycemic group were 974.37 and 748.48 ng/mL, respectively, and the difference was statistically not significant (95% CI, 191.24-2849.53; p = 0.07). When the calculated cut-off point of 600.99 ng/mL was used, the proportion of patients with higher MMP-9 levels was significantly more in the hyperglycemic group compared with the ones in the non-hyperglycemic group (82.5% and 54.8%, respectively; OR = 3.88; p = 0.011). CONCLUSION: We concluded that the proportion of patients with MMP-9 level >600.99 ng/mL was significantly higher in acute ischemic stroke patients with hyperglycemia.ng/mL was significantly higher in acute ischemic stroke patients with hyperglycemia.

scholarly journals Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure

Stroke ◽  
2003 ◽  
Vol 34 (6) ◽  
Author(s):  
Ji Hoe Heo ◽  
Seo Hyun Kim ◽  
Kyung Yul Lee ◽  
Eun Hee Kim ◽  
Chong Kyu Chu ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Acute Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Stroke Patients ◽  
Metalloproteinase 9

scholarly journals Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients

2015 ◽  
Vol 17 (4) ◽  
pp. 385-390 ◽  
Author(s):  
Kinga Buraczynska ◽  
Jacek Kurzepa ◽  
Andrzej Ksiazek ◽  
Monika Buraczynska ◽  
Konrad Rejdak
Keyword(s):  
Gene Polymorphism ◽  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Stroke Patients ◽  
Metalloproteinase 9

Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls

2012 ◽  
Vol 45 (6) ◽  
pp. 483-489 ◽  
Author(s):  
Munir Rababah ◽  
Hans Worthmann ◽  
Milani Deb ◽  
Anita B. Tryc ◽  
Yue Tao Ma ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Healthy Controls ◽  
Stroke Patients ◽  
Blood Samples ◽  
Metalloproteinase 9

scholarly journals THE CORRELATION OF MATRIX METALLOPROTEINASE-9 WITH STROKE AND PREVALENCE, RISK FACTORS, AND KNOWLEDGE OF STROKE AMONG PALESTINIANS

2020 ◽  
pp. 33-39
Author(s):  
ROZAN ATTILI ◽  
HATEM A HEJAZ
Keyword(s):  
Risk Factors ◽  
Matrix Metalloproteinase ◽  
Research Study ◽  
Matrix Metalloproteinase 9 ◽  
Stroke Patients ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Associated Risk Factors ◽  
Palestinian Population ◽  
Metalloproteinase 9

Objectives: The research study aims to estimate the prevalence of the stroke, to evaluate the stroke associated risk factors, and to determine the factors and symptoms associated with the knowledge of the stroke among the Palestinian population. Furthermore, to find the association between matrix metalloproteinase-9 (MMP-9) levels and the stroke, the concentration of MMP-9 in the serum of stroke patients was measured. Methods: The research study includes a cross-sectional survey that was conducted. The serum MMP-9 levels were also measured in 11 stroke patients using an ELISA reader. Statistical analysis was performed by GraphPad Prism version 8. Sociodemographic characteristics of stroke patients associated with stroke among the Palestinian population were also obtained and analyzed. Results: The higher incidence of the stroke was in the patient’s ages between 51 and 60 years old, with 30 patients (46%) of the total stroke patients. The majority of the stroke patients 40 (60.6%) were having enough income. Most of the stroke patients (29, 43.9%) were none educated. The majority of the stroke patients 48 (72.2%) had a family member/s who has been diagnosed with a stroke. Most of the stroke patients 60 (90.9%) have sudden numbness, weakness in the face, arms, and legs. All the samples analyzed showed a marked increase in MMP-9 concentration. Conclusions: The prevalence of stroke and the high risk of stroke were high among adults aged ≥51 years in Palestine. Hypertension was the highest risk factor for stroke. The serum MMP-9 could be an important prognostic factor for the stroke.

Sign in / Sign up

Export Citation Format

Share Document